Porcine antiviral protein TRAF1 polyclonal antibody as well as preparation method and application thereof
The invention discloses a porcine antiviral protein TRAF1 polyclonal antibody as well as a preparation method and application thereof, and belongs to the technical field of biology. The preparation method comprises the following steps: after equivalently mixing and emulsifying TRAF1 recombinant protein and a Freund's adjuvant, immunizing an animal to obtain a polyclonal antibody; wherein the amino acid sequence of the TRAF1 recombinant protein is as shown in SEQ ID NO: 1. The specific polyclonal antibody is prepared by constructing prokaryotic and eukaryotic expression vectors of the swine TRAF1 gene, and it is verified that the polyclonal antibody can be specifically combined with prokaryotic expression and eukaryotic expression TRAF1 protein, and after swine fever (CSFV) infects PK-15 cells, the expression level of the TRAF1 protein is remarkably improved; the in-vitro overexpression of the TRAF1 can significantly inhibit the replication of the CSFV. Therefore, the polyclonal antibody prepared by the invention can be applied to detection of TRAF1 or identification of interaction of TRAF1 and CSFV, and lays a foundation for deep exploration and understanding of an interaction mechanism of CSFV and TRAF1 protein and functions and cellular immune mechanisms of CSFV and TRAF1 protein in a signal channel..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 18. Apr. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LUO TINGRONG [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-04-18, Last update posted on www.tib.eu: 2023-09-26, Last updated: 2023-09-29 |
|---|
| Patentnummer: |
CN115975022 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA001628674 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA001628674 | ||
| 003 | DE-627 | ||
| 005 | 20240327212859.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240327s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA001628674 | ||
| 035 | |a (EPA)CN115975022 | ||
| 035 | |a (EPA)85966108 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LUO TINGRONG |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Porcine antiviral protein TRAF1 polyclonal antibody as well as preparation method and application thereof |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-04-18, Last update posted on www.tib.eu: 2023-09-26, Last updated: 2023-09-29 | ||
| 520 | |a The invention discloses a porcine antiviral protein TRAF1 polyclonal antibody as well as a preparation method and application thereof, and belongs to the technical field of biology. The preparation method comprises the following steps: after equivalently mixing and emulsifying TRAF1 recombinant protein and a Freund's adjuvant, immunizing an animal to obtain a polyclonal antibody; wherein the amino acid sequence of the TRAF1 recombinant protein is as shown in SEQ ID NO: 1. The specific polyclonal antibody is prepared by constructing prokaryotic and eukaryotic expression vectors of the swine TRAF1 gene, and it is verified that the polyclonal antibody can be specifically combined with prokaryotic expression and eukaryotic expression TRAF1 protein, and after swine fever (CSFV) infects PK-15 cells, the expression level of the TRAF1 protein is remarkably improved; the in-vitro overexpression of the TRAF1 can significantly inhibit the replication of the CSFV. Therefore, the polyclonal antibody prepared by the invention can be applied to detection of TRAF1 or identification of interaction of TRAF1 and CSFV, and lays a foundation for deep exploration and understanding of an interaction mechanism of CSFV and TRAF1 protein and functions and cellular immune mechanisms of CSFV and TRAF1 protein in a signal channel. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a G01N: Investigating or analysing materials by determining their chemical or physical properties (measuring or testing processes other than immunoassay, involving enzymes or microorganisms c12m, c12q) | |
| 650 | 4 | |a tec | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a LI XIAONING |4 aut | |
| 700 | 0 | |a CHO SANG-SOO |4 aut | |
| 700 | 0 | |a TANG RONGZE |4 aut | |
| 700 | 0 | |a ZHANG LIYUAN |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 18. Apr. |
| 773 | 1 | 8 | |g year:2023 |g day:18 |g month:04 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/85966108/publication/CN115975022A1?q=CN115975022 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 18 |c 04 | ||